Merck shuts down SeQuant

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Attrogy (diflunisal) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

A new, mid-size Contract Development Manufacturing Organisation (CDMO), Meribel Pharma Solutions, has launched with an integrated network across Europe.

OncoZenge and Avernus Pharma General Trading, a pharma marketing company from the UAE, have signed an exclusive agreement to license BupiZenge for commercialization and distribution in the Gulf Cooperation Council (GCC) region.

EQT and KKR has announced that EQT VIII fund has agreed to sell Karo Healthcare to KKR.

Circio Holding (former Targovax) and Entos Pharmaceuticals have announced the initiation of a research collaboration.

Oncopeptides has announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5.

The company has entered into a binding agreement with Molteni Farmaceutici regarding exclusive rights to commercialize BupiZenge in Europe.